Neurobiology of Heroin Addiction and of Methadone Treatment

ADDICTION AND THE BRAIN

There are eight families of addictive drugs, which are different in many ways, but similar in one important respect — whether it is nicotine or alcohol or cocaine or heroin, some people lose control and become compulsive users. The hallmark of addiction is compulsive use. Addiction is “a behavioral pattern of drug use, characterized by overwhelming involvement with the use of a drug (compulsive use), the securing of its supply, and a high tendency to relapse after withdrawal” (J. H. Jaffe, 1985).

Recent years have seen great advances in our understanding of this compulsive behavior. As all behavior is rooted in the brain, our new knowledge about addiction comes directly from basic brain research.

Every addictive drug used by people is also self-administered by rats and monkeys. If we arrange matters so that when an animal presses a lever, it gets a shot of heroin into a vein, that animal will press the lever repeatedly, to the exclusion of other activities (food, sex, etc.); it will become a heroin addict. A rat addicted to heroin is not rebelling against society, is not a victim of socioeconomic circumstances, is not a product of a dysfunctional family, and is not a criminal. The rat’s behavior is simply controlled by the action of heroin (actually morphine, to which heroin is converted in the body) on its brain.

We are beginning to learn why a laboratory animal (or a person) uses these drugs. A bundle of nerve cells (neurons) deep in the brain, the so-called mesolimbic dopaminergic pathway, is the main site of action of opiates like heroin — and also, interestingly, of all other addictive drugs. We call this the “reward pathway”. It mediates feelings of pleasure and satisfaction. Within the reward pathway, opiates indirectly cause dopamine neurons to release their dopamine. These dopamine neurons are held constantly in check by inhibitory neurons. Opiates act on those inhibitory neurons, shutting them down, removing the inhibition and thus allowing the dopamine neurons to run wild. Inhibition of inhibition causes stimulation.

An analogy may help. Dopamine, in that part of the brain, could be called a “pleasure hormone”; its release causes feelings of satisfaction, of euphoria. The dopamine neurons are held constantly in check by another neurotransmitter released from inhibitory neurons. If a dopamine neuron is like the accelerator pedal in a car, the inhibitory neuron is like the brake pedal, keeping the car from going too fast. Then endorphin neurons, in turn, hold the inhibitory neurons in check, prevent too much braking action and tend to let the car speed up. The net result is to keep the speed just right. A complicated way to run a car, a complicated way to run a brain; but an efficient way to maintain precise control. Thus, in short, opiates like heroin, mimicking the endorphins, cause more dopamine release, cause euphoria; but they do so in an uncontrolled way, overriding the natural controls.

We have learned the structure of the mu opioid receptors, on which the endorphins — and also, of course, opiates like morphine (from heroin) and methadone — act. These receptors are the locks that are unlocked by the endorphin (or opiate) keys. We know exactly how each of the several hundred amino acids in the receptor protein is positioned. Seven segments span the nerve cell membrane, back and forth, forming the staves of a barrel. A molecule of an endorphin (or morphine or methadone), passing from a blood capillary onto a neuron, would drop into the pocket in the middle of the barrel. When the molecular key drops into the lock, it changes the shape of the receptor, and a “signal” is sent to the inside of the cell. That “signal” triggers big chemical changes, which make that neuron less active, so it releases less of its neurotransmitter. The neurons containing mu opioid receptors, which are activated by endorphins or opiates, are the ones that hold the dopamine neurons in check, as already described, and the net result is to stimulate the release of more dopamine.

Our normal feelings of satisfaction, our good moods, are controlled by the regulation of dopamine release by endorphins acting on mu opioid receptors, as described. Heroin is rapidly converted in the body to morphine and 6-acetylmorphine, which act on these same receptors in the brain. The brain responds with feelings of euphoria, but the dopamine stimulation is excessive — far greater than when under the fine-tuned natural control of the endorphins. The brain adapts to this changed condition. It becomes less sensitive to opioids through several mechanisms I shall not discuss here. There are two important consequences of this adaptation. First, more heroin is now required to produce the desired “high”; and second, the system has become less sensitive to the endorphins, so that without heroin, there is insufficient dopamine release, and an uncomfortable feeling we describe as “dysphoria” (and the addict calls “sick”). Thus, after repetitive use of heroin, at increasing dosages, the addict has become tolerant and dependent, and undergoes withdrawal disturbances if the heroin is abruptly terminated.

TWO KEY QUESTIONS ABOUT ADDICTION

FIRST KEY QUESTIONWhy do some people become addicted in the first place, and others not? Why do some people not even like the psychoactive effects of an addictive drug and therefore never start using it? Why can some people use such a drug in moderation and never go on to heavy use and addiction? This extreme variability among people is typical for every addictive drug, from nicotine and alcohol to cocaine and heroin. Might there be some people whose reward pathway is defective in some way from birth, who can only feel “normal” on an opiate, for example, and who discover this the first time they encounter heroin?

SECOND KEY QUESTION: Since withdrawal discomfort is now readily controlled with various medications, so that an addict can be brought without difficulty to an abstinent state, why doesn’t that solve the problem? Why is relapse so common? Is it because of innate deficiencies in the reward pathway, or because chronic exposure to an opiate has caused irreversible changes? In either case, there may be addicts who can not function normally on their own supply of endorphins but require some opiate (like methadone) to occupy the receptors.

Source:
Neurobiology of Heroin Addiction and of Methadone Treatment
By: Avram Goldstein, M.D.
Professor Emeritus of Pharmacology, Stanford University

Visit the aatod conference website for more details…www.aatodconference.com.

@aatod1984
  • 💻Webinar Alert 
11/20, 12:30 PM - 2:00 PM EST
AATOD will present a complimentary webinar on Understanding #Telehealth Induction with #Methadone and #Buprenorphine in OTPs Under the New @samhsagov Regulations.

Mark Parrino, AATOD President, will serve as the host of this webinar along with principal speaker, Dr. Neeraj Gandotra, Chief Medical Officer for SAMHSA.

There will be ample time for Q&A and this webinar will become available to the public for On-Demand viewing via the AATOD website.

Register ➡️ bit.ly/40Kc8LC
  • 🔈AATOD & COMPA on Spectrum News — NY conference highlights new regulations expanding opioid treatment access #OUD #expandingaccesstotreatment
🖥️➡️bit.ly/4eGncNN
  • 💻 Our Association presented a complimentary webinar on the utilization of medications in correctional settings.

#ICYMI, please use this link to view full recording 
⬇️ 
bit.ly/4embfwf
  • 💻 Our Association will present a complimentary webinar on the utilization of medications in correctional settings on September 11, 2024 from 12:00 PM - 1:30 PM EST.

Mark Parrino, AATOD President, will serve as the host along with presenter, Linda Hurley of CODAC Behavioral Healthcare. Ms. Hurley will provide guidance to OTPs on how to work with correctional facilities on how to provide access to #MAT for #OUD.

REGISTER ➡️ bit.ly/3XjZPlV
  • International Overdose Awareness Day (IOAD) – held on August 31 every year – is the world’s largest annual campaign to end overdose, remember without stigma those who have died and acknowledge the grief of family and friends left behind.

The theme for 2024 is “Together we can”, highlighting the power of our community when we all stand together.
#IOAD2024 #TogetherWeCan #EndOverdose

Please view video message from AATOD's President, Mark Parrino ➡️bit.ly/3XpKyRz
  • Welcome to the #aatod2024 Conference
  • Welcome to Las Vegas. We invite you to attend this evening’s AATOD Board meeting ➡️ bit.ly/4apbmVt #aatod2024
  • Join us for the highly acclaimed 8-hour clinician’s course which convenes on Sunday, May 19, 2024 ➡️ bit.ly/3UOKtVi
#aatod2024
  • 📰 AATOD Unites Global Leaders in Opioid Use Disorder Treatment for Pivotal Las Vegas Summit 
➡️https://prn.to/3wEvR2G #OUD #somuchmorethanmedication #aatod2024
  • 💻 Welcome Message from Dr. Dinita Smith, Psy.D, MSW - #aatod2024 Conference Chair 

Thank you to our generous Conference Sponsors, Hosts, Exhibitors, Keynote Speakers, Presenters, Volunteers, and the entire Conference Planning Committee.

Online registration is still available. We look forward to welcoming you to Las Vegas!
💻Webinar Alert 
11/20, 12:30 PM - 2:00 PM EST
AATOD will present a complimentary webinar on Understanding #Telehealth Induction with #Methadone and #Buprenorphine in OTPs Under the New @samhsagov Regulations.

Mark Parrino, AATOD President, will serve as the host of this webinar along with principal speaker, Dr. Neeraj Gandotra, Chief Medical Officer for SAMHSA.

There will be ample time for Q&A and this webinar will become available to the public for On-Demand viewing via the AATOD website.

Register ➡️ bit.ly/40Kc8LC
💻Webinar Alert 11/20, 12:30 PM - 2:00 PM EST AATOD will present a complimentary webinar on Understanding #Telehealth Induction with #Methadone and #Buprenorphine in OTPs Under the New @samhsagov Regulations. Mark Parrino, AATOD President, will serve as the host of this webinar along with principal speaker, Dr. Neeraj Gandotra, Chief Medical Officer for SAMHSA. There will be ample time for Q&A and this webinar will become available to the public for On-Demand viewing via the AATOD website. Register ➡️ bit.ly/40Kc8LC
5 days ago
View on Instagram |
1/10
🔈AATOD & COMPA on Spectrum News — NY conference highlights new regulations expanding opioid treatment access #OUD #expandingaccesstotreatment
🖥️➡️bit.ly/4eGncNN
🔈AATOD & COMPA on Spectrum News — NY conference highlights new regulations expanding opioid treatment access #OUD #expandingaccesstotreatment 🖥️➡️bit.ly/4eGncNN
1 month ago
View on Instagram |
2/10
💻 Our Association presented a complimentary webinar on the utilization of medications in correctional settings. #ICYMI, please use this link to view full recording ⬇️ bit.ly/4embfwf
2 months ago
View on Instagram |
3/10
💻 Our Association will present a complimentary webinar on the utilization of medications in correctional settings on September 11, 2024 from 12:00 PM - 1:30 PM EST.

Mark Parrino, AATOD President, will serve as the host along with presenter, Linda Hurley of CODAC Behavioral Healthcare. Ms. Hurley will provide guidance to OTPs on how to work with correctional facilities on how to provide access to #MAT for #OUD.

REGISTER ➡️ bit.ly/3XjZPlV
💻 Our Association will present a complimentary webinar on the utilization of medications in correctional settings on September 11, 2024 from 12:00 PM - 1:30 PM EST. Mark Parrino, AATOD President, will serve as the host along with presenter, Linda Hurley of CODAC Behavioral Healthcare. Ms. Hurley will provide guidance to OTPs on how to work with correctional facilities on how to provide access to #MAT for #OUD. REGISTER ➡️ bit.ly/3XjZPlV
3 months ago
View on Instagram |
4/10
International Overdose Awareness Day (IOAD) – held on August 31 every year – is the world’s largest annual campaign to end overdose, remember without stigma those who have died and acknowledge the grief of family and friends left behind. The theme for 2024 is “Together we can”, highlighting the power of our community when we all stand together. #IOAD2024 #TogetherWeCan #EndOverdose Please view video message from AATOD's President, Mark Parrino ➡️bit.ly/3XpKyRz
3 months ago
View on Instagram |
5/10
Welcome to the #aatod2024 Conference
6 months ago
View on Instagram |
6/10
Welcome to Las Vegas. We invite you to attend this evening’s AATOD Board meeting ➡️ bit.ly/4apbmVt #aatod2024
Welcome to Las Vegas. We invite you to attend this evening’s AATOD Board meeting ➡️ bit.ly/4apbmVt #aatod2024
6 months ago
View on Instagram |
7/10
Join us for the highly acclaimed 8-hour clinician’s course which convenes on Sunday, May 19, 2024 ➡️ bit.ly/3UOKtVi
#aatod2024
Join us for the highly acclaimed 8-hour clinician’s course which convenes on Sunday, May 19, 2024 ➡️ bit.ly/3UOKtVi #aatod2024
6 months ago
View on Instagram |
8/10
📰 AATOD Unites Global Leaders in Opioid Use Disorder Treatment for Pivotal Las Vegas Summit 
➡️https://prn.to/3wEvR2G #OUD #somuchmorethanmedication #aatod2024
📰 AATOD Unites Global Leaders in Opioid Use Disorder Treatment for Pivotal Las Vegas Summit ➡️https://prn.to/3wEvR2G #OUD #somuchmorethanmedication #aatod2024
6 months ago
View on Instagram |
9/10
💻 Welcome Message from Dr. Dinita Smith, Psy.D, MSW - #aatod2024 Conference Chair Thank you to our generous Conference Sponsors, Hosts, Exhibitors, Keynote Speakers, Presenters, Volunteers, and the entire Conference Planning Committee. Online registration is still available. We look forward to welcoming you to Las Vegas!
6 months ago
View on Instagram |
10/10

💻Webinar Alert
11/20, 12:30 PM - 2:00 PM EST.
AATOD will present a complimentary webinar on Understanding #Telehealth Induction with #Methadone and #Buprenorphine in OTPs Under the New @samhsagov Regulations.
Register ➡️ http://bit.ly/40Kc8LC

Load More...

AATOD, Inc.
225 Varick Street, Suite 402
New York, New York 10014

Contact Us
Phone : 212-566-5555
Email : info@aatod.org

Social Sharing
RSS
Follow by Email
Facebook
Twitter
YouTube
LinkedIn
Instagram

Stay Connected to AATOD